Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing incidence and prevalence of colorectal cancer
3.2.1.2 Technological advancements in colorectal cancer therapeutics
3.2.1.3 Increased awareness and early detection
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost and side effects associated with therapies
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Therapy, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Chemotherapy
5.3 Immunotherapy
5.4 Other therapies
Chapter 6 Market Estimates and Forecast, By Cancer Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Colorectal adenocarcinoma
6.3 Gastrointestinal carcinoid tumors
6.4 Other cancer types
Chapter 7 Market Estimates and Forecast, By Treatment Provider, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals
7.3 Specialty clinics
7.4 Cancer research institutes
Chapter 8 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Netherlands
8.3.7 Rest of Europe
8.4 Asia Pacific
8.4.1 China
8.4.2 Japan
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Amgen Inc.
9.2 Bayer AG
9.3 Bristol-Myers Squibb Company
9.4 Celleron Therapeutics
9.5 Eli Lilly and Company
9.6 F. Hoffmann-La Roche Ltd.
9.7 Genentech, Inc.
9.8 Novartis AG
9.9 Pfizer Inc.
9.10 Sanofi S.A.
9.11 Sumitomo Pharma Co., Ltd.
9.12 Regeneron Pharmaceuticals, Inc.
9.13 TAIHO PHARMACEUTICAL CO., LTD
9.14 Takeda Pharmaceutical Company Limited
9.15 Teva Pharmaceutical Industries Ltd.
